U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Drug Trials Snapshot: ATTRUBY
  1. Drug Approvals and Databases

Drug Trials Snapshot: ATTRUBY

HOW TO USE THIS SNAPSHOT

The information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, and whether there were differences among sex, race, age, and ethnic groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.

LIMITATIONS OF THIS SNAPSHOT:

Do not rely on Snapshots to make decisions regarding medical care. Always speak to your healthcare provider about the benefits and risks of a drug.

Some of the information in this Snapshot is for presentation purposes and does not represent the approved conditions of use of this drug. Refer to the ATTRUBY Prescribing Information for all the approved conditions of use of this drug (e.g., indication(s), population(s), dosing regimen(s), safety information).

Snapshots are limited to the information available at the time of the original approval of the drug and do not provide information on who participated in clinical trials that supported later approvals for additional uses of the drug (if applicable).

ATTRUBY (acoramidis)
ah-troo-be
BridgeBio Pharma, Inc.
Original Approval date: November 22, 2024


DRUG TRIALS SNAPSHOT SUMMARY:

What is the drug for?

ATTRUBY is a transthyretin stabilizer that is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular (CV) death and CV-related hospitalization.

How is this drug used?

ATTRUBY is a tablet that is taken orally twice daily.

Who participated in the clinical trials?

The FDA approved ATTRUBY based on evidence of efficacy and safety from a clinical trial of 611 patients with wild-type or variant (hereditary or de novo) transthyretin cardiomyopathy (ATTR CM). The safety population comprised of 421 trial participants.

The trial was conducted at 95 sites in 18 countries including the United States, United Kingdom, Australia, Italy, Spain, Denmark, Canada, Czech Republic, New Zealand, Belgium, Israel, Netherlands, Greece, Brazil, Ireland, South Korea, Poland, and Portugal.

Of the 632 randomized patients in the trial, 126 (20%) patients (80 on ATTURBY, 46 on placebo) were from the United States.

How were the trials designed?

ATTRUBY was evaluated in a single phase 3 clinical trial of 611 patients with ATTR-CM.

Trial AG10-301 was a two-arm, double-blind, parallel design trial with 632 subjects randomized in a 2:1 ratio to ATTRUBY 712 mg twice daily (equivalent to 800 mg acoramidis HCl) or matching placebo (421 to ATTRUBY and 211 to placebo) and followed for 30 months at which time all randomized subjects were eligible to enroll in the open-label extension trial (AG10-304).

The trial featured an embedded design with Part A cohort consisting of a 12-month functional and health-related quality of life endpoints, and Part B cohort consisting of a 30-month mortality, morbidity, and functional endpoints. Part A did not meet its primary endpoint of change from baseline in 6-Minute Walk Distance (6MWD) at Month 12 (difference in least-squares [LS] mean: -2 meters, p=0.76) and Part B continued as specified in the protocol. The efficacy analyses are based on the results from AG10-301 Part B.

DEMOGRAPHICS SNAPSHOT

Figure 1 summarizes how many male and female patients were enrolled in the clinical trial used to evaluate the efficacy of ATTRUBY.

Figure 1. Baseline Demographics by Sex, Efficacy Population

Pie chart summarizing how many male and female patients were in the clinical trial. In total, 555 (91%) male patients and 56 (9%) female patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 2 summarizes how many patients by race were enrolled in the clinical trial used to evaluate the efficacy of ATTRUBY.

Figure 2. Baseline Demographics by Race, Efficacy Population

 Pie chart summarizing how many White, Black or African American, Asian, and other patients were in the clinical trial. In total, 537 (88%) White patients, 29 (5%) Black or African American patients, 13 (2%) Asian patients, and 32 (3%) other patients participated in the clinical trial.

Source: Adapted from FDA Review

Figure 3 summarizes how many patients by age were enrolled in the clinical trial used to evaluate the efficacy of ATTRUBY.

Figure 3. Baseline Demographics by Age, Efficacy Population

Pie chart summarizing how many patients by age were in the clinical trial. In total, 299 (49%) patients younger than 78 years of age and 312 (51%) patients 78 years of age and older participated in the clinical trial.

Source: Adapted from FDA Review

Figure 4 summarizes how many patients by ethnicity were enrolled in the clinical trial used to evaluate the efficacy of ATTRUBY.

Figure 4. Baseline Demographics by Ethnicity, Efficacy Population

Pie chart summarizing how many Hispanic, not Hispanic, and not reported or unknown patients were in the clinical trial. In total, 11 (2%) Hispanic or Latino patients, 582 (95%) not Hispanic or Latino patients, and 18 (3%) not reported or unknown patients participated in the clinical trial.

Source: Adapted from FDA Review

What are the benefits of this drug? 

Trial AG10-301 demonstrated that ATTRUBY reduces the risk of CV death and CV-related hospitalization and improves functional capacity and symptoms in patients with ATTR-CM. ATTRUBY belongs to the same drug class as the already approved drug, tafamidis. Hence, ATTRUBY represents another treatment option for patients with ATTR-CM.

Were there any differences in how well the drug worked in clinical trials among sex, race, age, and ethnicity? 

  • Sex: The effect of ATTURUBY was similar for males and females.
  • Race: The number of patients of races other than White was small; therefore, differences in how ATTURUBY worked among races could not be determined.
  • Age: The effect of ATTURUBY was similar in patients younger and older than 78 years of age.
  • Ethnicity: The number of patients of ethnicities other than Not Hispanic or Latino was small; therefore, differences in how ATTURUBY worked according to ethnicity could not be determined.

What are the possible side effects?

The key safety risks with ATTRUBY are mild, gastrointestinal adverse reactions such as diarrhea and upper abdominal pain that generally do not require treatment discontinuation.

Were there any differences in side effects among sex, race, and age?

  • Sex: The occurrence of side effects was similar in males and females.
  • Race: The majority of patients were White. The number of patients of other races was limited; therefore, differences in side effects among races could not be determined.
  • Age: The occurrence of side effects was similar in patients younger and older than 65 years of age.

GLOSSARY

CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments.

COMPARATOR: A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested.

EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial.

PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.

SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.

LINK TO DRUG PACKAGE INSERT

Back to Top